A Single-Center, Two-Arm, Open-Label Phase IIA Clinical Trial to Investigate Efficacy and Safety of Ritlecitinib in Patients With Keloid
Latest Information Update: 03 Oct 2024
Price :
$35 *
At a glance
- Drugs Ritlecitinib (Primary)
- Indications Keloids
- Focus Therapeutic Use
- 12 Jul 2024 Planned initiation date (estimated date of first participant enrollment) changed from 30 Jun 2024 to 1 Sep 2024.
- 03 Jun 2024 Planned initiation date changed to 30 Jun 2024.
- 22 Apr 2024 New trial record